De Lisle Partners LLP Blueprint Medicines Corp Transaction History
De Lisle Partners LLP
- $617 Billion
- Q3 2024
A detailed history of De Lisle Partners LLP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, De Lisle Partners LLP holds 5,000 shares of BPMC stock, worth $458,100. This represents 0.07% of its overall portfolio holdings.
Number of Shares
5,000
Previous 5,000
-0.0%
Holding current value
$458,100
Previous $539 Million
14.29%
% of portfolio
0.07%
Previous 0.12%
Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
351Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$612 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$609 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$494 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$363 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$253 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.47B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...